Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Maria R. Baer"'
Autor:
Jonathan Cornu, Vu H. Duong, Alison Duffy, Maria R. Baer, Sandrine Niyongere, Jummai Apata, Ciera L Patzke, Noa G. Holtzman, Sarah M. Kashanian, Ashkan Emadi, Farin Kamangar, Madhurima Koka
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:817-826
Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL
Autor:
Maria R. Baer, Amol C. Shetty, Elizabeth T. Chang, Sandrine Niyongere, Erin T. Strovel, Rena G. Lapidus, Ronald B. Gartenhaus, Kayla M. Tighe, Bandish Kapadia, Brandon Carter-Cooper, Ashkan Emadi, Anup Mahurkar, Farin Kamangar, Binny Bhandary, Dominique R Bollino, Xinrong Ma, Eun Yong Choi, Curt I. Civin, Blake S. Moses, Hannah Kaizer
Publikováno v:
Leukemia. 35:1907-1924
Complex karyotype acute myeloid leukemia (CK-AML) has a dismal outcome with current treatments, underscoring the need for new therapies. Here, we report synergistic anti-leukemic activity of the BCL-2 inhibitor venetoclax (Ven) and the asparaginase f
Autor:
Yang Liu, Sami N. Malek, Brian Parkin, Yin Wang, Duxin Sun, Miao He, Yan Liu, Maria R. Baer, Peng Zhang, Pan Zheng, Huixia Zhang, Christopher Bailey
Publikováno v:
Oncogene
TP53 mutation in acute myeloid leukemia (AML) is associated with poor prognosis. Since no targeted therapy is available to restore p53 function, it is of great interest to test whether other pathways activated by TP53 mutations can be therapeutically
Autor:
Robert K. Stuart, Je-Hwan Lee, Andreas Neubauer, Jorge E. Cortes, Richard A. Larson, Timothy S. Pardee, Mark J. Levis, Chaofeng Liu, Harry P. Erba, Sung Soo Yoon, Celalettin Ustun, Ellin Berman, Maria R. Baer, Nikolai A. Podoltsev, Wen-Chien Chou, Giovanni Martinelli, Nahla Hasabou, Pau Montesinos, Antonio Di Stasi, Stefania Paolini, Alexander E. Perl, Francesco Fabbiano, Hisayuki Yokoyama, Xuan Liu, Margaret Kasner, Rebecca L. Olin, Naoko Hosono, Erkut Bahceci, Amir T. Fathi, Fabio Ciceri, Christian Recher
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
BACKGROUND Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor
Autor:
Eric A. Gehrie, Maria R. Baer, Gabriel Ghiaur, Kyle Zacholski, Ivana Gojo, Amy E. DeZern, Matthew J Newman, Ashkan Emadi, Sarah M. Kashanian, B. Douglas Smith, Andrew Y. Li, Ravi Varadhan, Erin Hickey, Bryan C. Hambley, Mark J. Levis, Vu H. Duong
Publikováno v:
J Oncol Pharm Pract
Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) combination therapy yields high complete remission and disease-free survival rates in acute promyelocytic leukemia (APL). ATO is dosed on actual body weight and high ATO doses in overweight pa
Autor:
Eugene Zhu, Maria R. Baer, Dietger Niederwieser, Olatoyosi Odenike, Souria Dougherty, Laurie Sherman, Libo Sun, John Mascarenhas, Aleksandra Rizo, Fei Huang, Rami S. Komrokji, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Bruno Martino, Francesca Palandri, Ying Wan, Jacqueline Bussolari, Ronald Hoffman, Faye Feller, Andreas Reiter, Esther Rose
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(26)
PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase i
Autor:
Pau Montesinos, Farhad Ravandi, Martha Arellano, Karen Seiter, Ellin Berman, Jessica K. Altman, Lori J. Maness, Donald P. Quick, Parameswaran Venugopal, Judy H. Chiao, Scott R. Solomon, Rakesh Gaur, Mikkael A. Sekeres, Maria R. Baer, Marc Buyse, Aleksandra Butrym, David A. Rizzieri, Stephen A. Strickland, Stuart L. Goldberg, Tapan M. Kadia, Marc Gautier, David F. Claxton, Gary J. Schiller, Gianluca Gaidano, Kebede H. Begna, Selina M. Luger, Hagop M. Kantarjian, Xavier Thomas
Publikováno v:
Cancer
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alt
Autor:
Amy E. DeZern, Maria R. Baer, B. Douglas Smith, Mark E. Sutherland, Firas El Chaer, Alison Duffy, Mark J. Levis, Ciera L Patzke, Andrew Y. Li, Noa G. Holtzman, Moaath Mustafa Ali, Gabriel Ghiaur, Kelly J. Norsworthy, Sarah M. Kashanian, Jonathan Cornu, Mohammad Imran, Ivana Gojo, Vu H. Duong, Bryan C. Hambley, Kyle Zacholski, Ashkan Emadi
Publikováno v:
EJHaem
INTRODUCTION: Obesity has become increasingly prevalent worldwide and is a risk factor for many malignancies. We studied the correlation between body mass index (BMI) and the incidence of acute promyelocytic leukemia (APL), non-APL acute myeloid leuk
Autor:
Maria R. Baer, Noa G. Holtzman, Gabriel Ghiaur, Firas El Chaer, Amy E. DeZern, Ivana Gojo, Bryan C. Hambley, Kyle Zacholski, Ashkan Emadi, Vu H. Duong, Sarah M. Kashanian, Kelly J. Norsworthy, Andrew Y. Li, B D Smith, Jonathan Webster, Farin Kamangar, Mark J. Levis
Publikováno v:
Biology
Biology, Vol 10, Iss 243, p 243 (2021)
Biology, Vol 10, Iss 243, p 243 (2021)
Simple Summary Around 12–38% of acute promyelocytic leukemia (APL) patients carry the FLT3-ITD mutation, which has been associated with several poor-prognosis indicators such as high white blood cell counts, M3v variant morphology, and the bcr3 iso
Autor:
John Mascarenhas, Marina Kremyanskaya, Mohamed E. Salama, Abdulraheem Yacoub, Craig M. Kessler, Dmitriy Berenzon, Ellen K. Ritchie, Joseph Vadakara, Damiano Rondelli, Rona Singer Weinberg, Elliot F. Winton, Richard T. Silver, Alessandro M. Vannucchi, Raajit K. Rampal, Ruben A. Mesa, Vesna Najfeld, Alessandro Rambaldi, Maria Chiara Finazzi, Joseph Tripodi, Robert S. Hoffman, Elizabeth O. Hexner, David S. Leibowitz, Murat O. Arcasoy, J. T. Prchal, Vittorio Rosti, Noushin Farnoud, Amylou C. Dueck, Rosalind Catchatourian, Maria R. Baer, Judith D. Goldberg, Lonette Sandy, Heidi E. Kosiorek
Publikováno v:
Leukemia
Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms (MPNs) characterized by an increased risk of developing venous and arterial thromboses and of evolution to myelofibrosis or acute leukemia (1). MPNs are recogn